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Abstract
Background: Natural products have played an important role as leads for the development of new drugs against
malaria. Recent studies have shown that maslinic acid (MA), a natural triterpene obtained from olive pomace,
which displays multiple biological and antimicrobial activities, also exerts inhibitory effects on the development of
some Apicomplexan, including Eimeria, Toxoplasma and Neospora. To ascertain if MA displays anti-malarial activity,
the main objective of this study was to asses the effect of MA on Plasmodium falciparum-infected erythrocytes in
vitro.
Methods: Synchronized P. falciparum-infected erythrocyte cultures were incubated under different conditions with
MA, and compared to chloroquine and atovaquone treated cultures. The effects on parasite growth were
determined by monitoring the parasitaemia and the accumulation of the different infective stages visualized in thin
blood smears.
Results: MA inhibits the growth of P. falciparum Dd2 and 3D7 strains in infected erythrocytes in, dose-dependent
manner, leading to the accumulation of immature forms at IC50 concentrations, while higher doses produced non-
viable parasite cells. MA-treated infected-erythrocyte cultures were compared to those treated with chloroquine or
atovaquone, showing significant differences in the pattern of accumulation of parasitic stages. Transient MA
treatment at different parasite stages showed that the compound targeted intra-erythrocytic processes from early-
ring to schizont stage. These results indicate that MA has a parasitostatic effect, which does not inactivate
permanently P. falciparum, as the removal of the compound allowed the infection to continue
Conclusions: MA displays anti-malarial activity at multiple intraerythrocytic stages of the parasite and, depending
on the dose and incubation time, behaves as a plasmodial parasitostatic compound. This novel parasitostatic effect
appears to be unrelated to previous mechanisms proposed for current anti-malarial drugs, and may be relevant to
uncover new prospective plasmodial targets and opens novel possibilities of therapies associated to host immune
response.
Background
Despite the increasing number of synthetic and natural
compounds which are reported to inhibit the infective
cycle of the malaria-related Plasmodium species [1-5]
only a few of them have been found to be useful in the
treatment and prevention of the disease [6]. Current
anti-malarial drugs have an effect on a limited selection
of plasmodial targets: inhibition of the conversion of
toxic haem to haemozoin in the vacuole (chloroquine,
quinine, mefloquine and other alkaloids), the inhibition
of synthesis of parasite nucleic acids by hindering of the
dihydrofolate pathway (pyrimethamine, sulphadoxine,
proguanil), the triggering of oxidative stress (artemisinin
and derivatives, primaquine) or inhibition of the mito-
chondrial electron transport chain (atovaquone). Some
drugs may affect multiple processes, like chloroquine,
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which may also cause oxidative damage at the erythro-
cytic stage [7]. The widespread use of the most effective
and affordable drugs, such as chloroquine and the anti-
folate combination pyrimetamine-sulphadoxine, has
favoured the appearance of resistant Plasmodium var-
iants making the control of the disease more difficult in
endemic areas [8]. Resistance to artemisinin has been
also recently reported [9,10]. Alternative existing medi-
cations are, on the other hand, virtually unaffordable in
the countries most seriously affected, or their efficacy
may be compromised in the near future by the emer-
gence of new resistant variants. Hence, the search of
new synthetic or natural compounds targeting novel
biochemical pathways or cell functions is still an
imperative need.
The search of natural products showing anti-malarial
activity for its direct use or as leads for new drugs is
one of the alternatives which are currently explored
[11]. Maslinic acid (2a,3b-dihydroxyolean-12-en-28-oic
acid) (MA) is natural olenane-type pentacyclic triterpene
found in the olive fruit and can be readily obtained
from olive pomace oils [12]. Several pharmacological
activities have been reported for this compound, such as
anti-tumor [13,14], anti-oxidant [15,16], HIV protease
inhibitor [17], antimicrobial [18], vasorelaxation [19],
and anti-diabetic action mediated by inhibition of glyco-
gen phosphorylase [20,21] and protein tyrosine phospha-
tase 1B [22]. In addition, it has been shown that MA
displays low toxicity on non-tumoral cells [23,24] indi-
cating that it should be safe for use in humans. Several
lines of evidence point to a possible anti-malarial activity
of MA. HIV protease inhibitors have been recently
shown to hinder the pre-erythrocytic stages of Plasmo-
dium [25]. Anti-parasitic activities of MA were also
identified against other Apicomplexans [26]. It has been
also proposed that the observed growth inhibition of
Toxoplasma gondii cultures treated with maslinic acid
may be related to inhibition of protease activity, leading
to defects in gliding motility and ultrastructural altera-
tions of the parasite [24]. Such a possibility suggests a
potential activity of maslinic acid, or structurally related
molecules, on parasitic processes different from those
targeted by current anti-malarial drugs. In addition,
other triterpenoid molecules structurally related to MA
display very different cytotoxic and antiparasitic activ-
ities. Thus, cucurbitane-type triterpenoids have been
recently shown to display anti-malarial activity [27],
while ursane-type urosolic acid was reported to inhibit
growth of Trypanosoma cruzi [28] showing in contrast
low anti-plasmodial activity [29]. However, hybrid mole-
cules consisting on ursolic acid bound to pharmaco-
phores showed enhanced inhibitory activity on
Plasmodium, presumably by facilitating the access of the
bound pharmacophore to haem [30]. Maslinic acid has
also been used as core compound to synthesize modified
derivatives displaying new activities: binding of hetero-
cyclic rings at MA C-2 and C-3 positions increase sig-
nificantly the inhibitory activity upon human protein
tyrosine phosphatase 1B [22], while attachment of
hydrophobic groups at C-28 increase inhibition of
human glycogen phosphorylase [31]. Coupling of amino
acids or dipeptides at C-28 allowed to retain the anti
HIV-1 activity while lowering alongside the cytotoxicity
[32]. Should MA show significant anti-malarial activity,
it would be feasible to use this molecule as a lead com-
pound for the development of a new family of highly
active and low toxic anti-plasmodial drugs.
To explore the suitability of maslinic acid as anti-
malarial agent, the activity of this triterpene on cultures
of P. falciparum 3D7 and the chloroquine-resistant Dd2
strains has been tested. As none of the currently used
anti-malarial drugs targets plasmodial proteases, MA
activity was compared to those of chloroquine and ato-
vaquone as examples of effective drugs which interfere
the intra-erythrocytic stage of the parasitic cycle.
Methods
Drugs and inhibitors
Maslinic acid (MA) was obtained from pressed fruits of
olive (Olea europaea) by a method previously published
[12]. Chloroquine diphosphate salt was purchased from
Sigma-Aldrich. Atovaquone was kindly provided by
Glaxo-SmithKline. Stock solutions of atovaquone
30 mM and MA 300 mM were prepared in 100%
dimethyl sulfoxide (DMSO). Chloroquine was dissolved
in distilled water at 100 mM. All compounds were stored
at -20°C until use. For the drug assays, serial dilutions
were made in culture medium and added to 96-well cul-
ture plates. Control cultures were treated with equivalent
amounts of DMSO diluted in culture medium.
In vitro cultures of Plasmodium falciparum
Plasmodium falciparum strains Dd2 (clone MRA-150)
and 3D7 (clone MRA-102) obtained from the MR4 [33]
were used for this study. Erythrocytes were obtained
from type A+ human healthy local donor and collected
in tubes with citrate-phosphate-dextrose anticoagulant
(Vacuette®). The culture media consisted of standard
RPMI 1640 (Sigma-Aldrich) supplemented with 0.5 %
Albumax I (Gibco), 100 μM hypoxanthine (Sigma-
Aldrich), 25 mM HEPES (Sigma-Aldrich), 12.5 μg/mL
gentamicine (Sigma-Aldrich) and 25 mM NaHCO3
(Sigma-Aldrich). Each culture was started by mixing
uninfected and infected erythrocytes to achieve a 1 %
haematocrit and incubated in 5% CO2 at 37°C in tissue
culture flasks (Iwaki). The progress of growth in the cul-
ture was determined by microscopy in thin blood
smears stained with Wright’s eosin methylene blue
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solution (Merck), using the freely available Plasmoscore
software [34] to monitor the parasitaemia. The detailed
description of the culture and synchronization methods
used have been reported previously [35].
Fluorimetric assays for anti-malarial drug activity
A PicoGreen® microfluorimetric DNA-based assay was
used to monitor parasite growth inhibition at different
drug concentrations [36]. PicoGreen® (P7589) was pur-
chased to Invitrogen and diluted as indicated by the man-
ufacturer in TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 7.5). Synchronized rings from stock cultures were
used to test 200 μM to 0.1 μM serial dilutions of maslinic
acid in 96-well culture microplates. Thus, 150 μL of para-
sites at 2% haematocrit and 1% parasitaemia were
allowed to grow for 48-hour in 5% CO2 at 37°C. The
parasites were then centrifuged at 600 × g for 10 minutes
and re-suspended in saponin (0.15%, w/v in phosphate-
buffered saline) to lyse the erythrocytes and release the
malaria parasites. To eliminate all traces of haemoglobin
the pellet was washed by the addition of 200 μL of PBS
followed by centrifugation at 600 × g. The washing step
was repeated twice to ensure complete removal of hae-
moglobin. Finally, pellets were re-suspended in 100 μL of
PBS. 100 μL of PicoGreen® diluted in TE were added to
each well. Plates were incubated for 30-60 minutes in the
dark and the fluorescence intensity was measured at 485
nm excitation and 528 nm emission. Growth inhibition
was calculated as previously described [36].
Assay for haem polymerization
The effect of drugs on haem polymerization was tested
in vitro as described previously [37]. Briefly, a mixture
containing 50 μL of 0.5 mg/ml haem (ferriprotoporphyrin
IX chloride from Fluka, HPLC purity > 98%, dissolved in
dimethylsulphoxide), 100 μL of 0.5 M sodium acetate
buffer pH 4.4 and 50 μL of drug solution or solvent (for
control), was incubated in a flat bottom 96-well plate
(Costar 3799) at 37°C for 48 h. Microplates were then
centrifuged at 3300 × g for 15 min. The supernatant was
discarded and the remaining pellet was resuspended with
200 μL DMSO to remove unreacted haemin. The micro-
plate was then centrifuged once again and the superna-
tant eliminated. The pellet consisting of b-haematin was
dissolved in 200 μL of 0.1 M NaOH for spectroscopic
quantification at 405 nm. The data were expressed as the
percentage of inhibition of haem polymerization calcu-
lated by the following equation: % inhibition = 100 × (O.
D. control - O.D. drug) / (O.D. control).
Effect of maslinic acid, chloroquine and atovaquone on
P. falciparum cultures
Synchronized mature rings (22 h) of P. falciparum Dd2
at 1% parasitaemia were incubated for 48 hours to
complete an infective cycle in the presence of different
concentrations of the drugs, and parasite morphology
was evaluated by microscopic analysis of Wright’s
-stained thin blood smears. Smears from drug-free cul-
tures were used as control.
Viability of P. falciparum cultures after treatment with
maslinic acid
Synchronous ring, trophozoite, or schizont-stage P. falci-
parum 3D7-infected erythrocytes at 10% parasitaemia
were incubated with 100 μM MA for 12 hr. All cultures
were started using a single synchronized culture from
which aliquots were taken at 12 h (young rings), 24 h
(trophozoites) and 36 h (schizonts) and treated with
MA for 12 hours, followed by MA removal by multiple
washes. Untreated cultures and cultures grown in the
presence of MA throughout the whole experiment were
run in parallel as controls. Stage-specific development
was assessed by examining a minimum of 1,000 parasi-
tized cells on each smear, for differential counting of
rings, trophozoites, schizonts, and pyknotic forms whose
developmental stage could not be established. The frac-
tion of each group was calculated as a percentage of the
total parasitized cells. Parasitaemia was measured by
counting 1,000 red cells and is reported as the percent
of parasitized erythrocytes. Parasite replication was eval-
uated from successive parasitaemia measurements at the
beginning of each new asexual cycle. Smears were made
each 12 h and stained. The cultures were monitored for
at least 90 hours, corresponding to approximately two
cycles of P. falciparum.
Results
Activity of maslinic acid on Plasmodium-infected
erythrocyte cultures
The effects of MA on the growth of P. falciparum 3D7
and the chloroquine resistant strain Dd2 on human ery-
throcyte cultures were determined by analysing the
dose-response curves in the 0.1 to 200 μM range by
using microfluorimetric assays on DNA-stained cultures
(Figure 1). The cultures showed a dose-dependent inhi-
bitory effect on the parasite growth. The IC50 obtained
for Dd2 and 3D7 were, respectively, 32 ± 2 and 26 ± 3
μM. The dose-response curves were almost indistin-
guishable for both strains. Similar dose-response curves
were obtained for chloroquine and atovaquone (not-
shown) yielding the following IC50: chloroquine 0.19
μM (Dd2), 0.014 μM (3D7); and atovaquone 0.8 nM
(Dd2), 1.1 nM (3D7) The comparable IC50 values for
maslinic acid found in chloroquine-resistant and non-
resistant strains suggests that this compound may affect
plasmodial processes different to those targeted by
chloroquine. The main anti-malarial activity of chloro-
quine appears to involve the inhibition of formation of
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haemozoin. To discard any interaction of MA with the
haemozoin process, a b-haematin polymerization test
was performed (Figure 2) which demonstrated that,
similarly to atovaquone, MA does not interfere with
such parasite activity.
To analyse the effects of MA on the maturation of the
parasite in the erythrocyte, and compare them to those
obtained with chloroquine and atovaquone, synchro-
nized Dd2 infected erythrocytes at mature ring stage
(1% parasitaemia) were treated with MA, chloroquine or
atovaquone at different concentrations during one infec-
tive cycle (48 hours), sampled and examined in thin
blood smears. As shown in figure 3, the untreated cul-
ture reached 8% parasitaemia and contained predomi-
nantly trophozoites at sampling time, indicating that a
complete invasive cycle had taken place, producing new
trophozoites. Cultures treated with MA at 30 μM (IC50
range) accumulated young rings at the same time, con-
comitant with a 50% reduction in parasitaemia as com-
pared to the untreated culture. The parasitaemia
increase suggests that the parasite was able to invade
new erythrocytes, although at lower rates, and the
observed accumulation of ring stage may account for
both first and delayed second generation parasites.
Higher MA concentrations led to the appearance of
pyknotic forms and a drastic decrease in parasitaemia
(0.1%) suggesting that such dosing was lethal for the
parasite. The dose-dependent effect of MA was further
demonstrated by a detailed survey of different parasite
stages after 48 h treatment (figure 3C). These results
suggest a slowdown of P. falciparum cell cycle at MA
concentrations nearing the IC50. At 30 μM there are
still schizonts from the previous cycle, together with
new rings which do not progress to trophozoites. Cul-
tures treated with 50 μM MA consisted mainly of tro-
phozoites, likely from the previous cycle as the absence
of increase in parasitaemia suggests, as well as pycnotic
forms. The lack of ring or schizont stages at this incuba-
tion time indicates that at 50 μM MA the parasite was
not able to complete the cycle to schizonts and infect
new erythrocytes. At their respective IC50, the profiles
of parasitic stages observed in the chloroquine and ato-
vaquone cultures were also consistent with a delayed
progress of parasite maturation, but showing differences
with the profile observed in MA-treated cultures. As
shown in the figure 3, 0.2 μM chloroquine-treated cul-
tures accumulated almost exclusively rings, while atova-
quone at 1 nM accumulates mainly schizonts,
Figure 1 Dose-response curve of maslinic acid on P. falciparum
infected erythrocytes. A. Structure of maslinic acid. B. P. falciparum
Dd2 (black circles) and 3D7 (white circles) strains were grown in
erythrocyte cultures at 1% initial parasitaemia and incubated with
different concentrations of maslinic acid. The DNA content was
determined at 48 hours by microfluorimetry. The calculated 50%
inhibitory concentration (IC50) values were 32 ± 2 for Dd2 and 26 ±
3 μM for 3D7. Results are the mean of three independent cultures.
Figure 2 Assay of b-haematin polymerization . Haem was
incubated in the presence of increasing amounts of maslinic acid
(open circle, dashed line), chloroquine (black circle, solid line) and
atovaquone (triangle, dotted line) for 48 h, and the formation of b-
haematin was determined spectrophotometrically at 405 nm.
Results are the mean ± SD of three independent experiments.
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Figure 3 Dose-dependent effects of maslinic acid on P. falciparum cultures compared to chloroquine and atovaquone. Synchronized
cultures of Dd2 at mature ring stage (22 h, 1% parasitaemia) were incubated for 48 hours with the compounds at the indicated concentrations
and compared to an untreated control. Cultures were evaluated by microscopic inspection of Wright’s-stained thin blood smears. A. Microscopic
images of P. falciparum cultures incubated with different concentrations of maslinic acid, chloroquine and atovaquone. Delayed trophozoites (Y)
and pyknotic forms (X) showing condensation of the parasite nucleus are highlighted. B. Parasitaemia of the previous cultures after 48 h MA
treatment. Results are the mean ± SD of three independent experiments. C. Parasitic stages observed in cultures treated with different
concentrations of MA, chloroquine and atovaquone for 48 hours. Bars show percentage of rings (white), trophozoites (grey), schizonts (black)
and pyknotic (hatched) forms observed in Dd2 cultures treated at the indicated compound concentrations. The percent of each group accounts
for the fraction of cells showing every parasite stage from a total of 1000 erythrocytes ± SD. Results are representative of 2 experiments.
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supporting a different mechanism of action for MA as
compared to those of chloroquine or atovaquone.
Effect of MA in the viability of Plasmodium intra-
erythrocytic cycle
As shown above, MA appears to arrest the progress of
the P. falciparum erythrocytic cycle in a dose-dependent
fashion, leading at high doses to the accumulation of
trophozoites and pycnotic forms. To ascertain if such
effect is reversible and the infection can continue after
removal of the compound, MA was added at 100 μM to
P. falciparum infected erythrocytes at either ring, tro-
phozoite or schizont stages. In this experiment, 100 μM
was used as a compromise between 30 μM, at which the
effects of MA would not be evident after 12 hours, and
200 μM, at which no viable cells are recovered and,
therefore, no recovery of parasite growth would be
expected. As similar IC50 for MA were observed for
Dd2 and 3D7, the viability assay was performed in 3D7.
After 12 h incubation, MA was removed and the parasi-
taemia was examined every 12 hours thereafter. The
results (Figure 4A) showed that all cultures were unable
to infect erythrocytes while MA was present, as no
increase in parasitaemia at 48 h was observed compared
to the untreated culture. All cultures treated transiently
with MA resumed the infection thereafter, revealing a
parasitostatic effect of MA. Specific treatments at ring
and trophozoite stages behave in a similar way, display-
ing identical recovery rates in parasitaemia values at 62
hours. When maslinic acid was added at the schizont
stage, and removed afterwards, the increase in parasitae-
mia was further delayed, showing a slow recovery at 74
hours. The recovery from the treatment was not
immediate at any tested dose. All cultures showed some
decrease in parasitaemia after removal of MA until 48
hours, and then a progressive increase of parasitized
cells. This behavior can be explained considering the
relative high dose of MA used, above the IC50. Under
these conditions, a fraction of parasites would be
expected to be killed, and only the survivors would be
able to resume growth. To examine the effect of these
incubations on the intracellular maturation of the para-
site, samples were collected at each time and visualized
in thin blood smears. As shown in Figure 4B, the 12
hour incubation periods with MA leads to the corre-
sponding delay in the appearance of the subsequent
infection stages. This is clearly evidenced in the 48
hours samples, which mostly display newly infected ery-
throcytes at ring stage in the untreated culture, while
treated cultures show schizont-stage parasites arrested
in the previous cycle. Figure 5 shows the statistics of the
different parasite stages recorded in the same experi-
ment. Ring-stage MA incubated cultures displayed a
sharp increase of rings at the end of the treatment (12
h), which subsequently progressed to trophozoites and
schizonts, showing an overall 12 hour delay as compared
to the untreated control. A similar effect could be
recorded both in the trophozoite and schizont-stage
treated cultures, with initial accumulation of tropho-
zoites or schizonts, respectively, and the progressive
appearance of more mature forms after removal of MA.
Remarkably, the recovery of the parasite after incubation
with MA appears to be slower when the treatment takes
place at mature stages: while rings are not detected 12 h
after ring-stage MA treatment, schizonts are still present
24 h after schizont-stage MA treated cultures. These
results are consistent with the interference of MA with
processes occurring between ring and early schizont
stages.
Discussion
In addition to the broad range of biological activities
previously reported for maslinic acid, this compound
displays also a significant inhibitory activity on the ery-
throcytic cycle of P. falciparum. Evaluation of IC50 for
MA by inhibition of DNA replication in vitro yields a
value in the range of 30 μM. This value is even lower
than the 54 μM IC50 previously reported for MA on T.
gondii [24]. The accumulation of rings observed in cul-
tures incubated with this concentration of MA for 48
hours suggest a delay in the progress of the parasite
maturation. However, incubation of infected erythrocyte
cells with 100 μM MA for 48 hours led to the appear-
ance of non-viable cells. Maslinic acid at concentrations
approaching the IC50 appears therefore to slowdown
the erythrocytic cycle of P. falciparum, while higher
doses may induce parasite cell death. In contrast,
infected cultures treated with IC50 concentrations of
chloroquine or atovaquone led to different parasite stage
profiles. Chloroquine 0.2 μM-treated cultures consisted
almost exclusively of ring-stage parasites, which may
correspond to cell-cycle delayed cells, similarly to the
dose-dependent delay recently reported for mefloquine-
treated 3D7, W2 and FCB strains [38]. Treatment with
atovaquone at 1 nM yields predominantly schizonts.
The proposed plasmodial target for atovaquone, an ubi-
quinone analog, is the mitochondrial bc1 cytochrome
complex which, once inactivated, leads to mitochondrial
membrane depolarization and ultimately, inhibition of
DNA synthesis [39]. Such mechanism of action may
explain the accumulation of mature forms of the
parasite.
Further evidence of the difference between MA and
chloroquine inhibitory mechanisms was obtained as MA
does not inhibit the accumulation of haematin, thus dis-
carding a possible inhibition of the synthesis haemozoin.
In addition the chloroquine-resistant Dd2 strain did not
show relevant differences in survival to MA. The
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Figure 4 Effect of transient treatment with MA at different plasmodial stages. A. Development of parasitaemia after maslinic acid
treatment at different growth stages of P. falciparum 3D7. Twelve-hours ring-stage synchronized cultures at 10% parasitaemia were incubated in
the presence of MA 100 μM for 12 hours at times corresponding to ring (R+MA), trophozoite (T+MA) and schizont (S+MA) stages. After
treatment, MA was removed and parasitaemia was monitored up to 86 h after culture synchronization: untreated (white triangles), R+MA (white
circles), T+MA (black circles), S+MA (black triangles), not-removed MA (black squares). Cycle time indicates the elapsed hours of the culture
started with synchronized 12 hour-old rings. Results are presented as arithmetic mean of three independent experiments ± SD. B. Morphological
changes observed in the transiently-treated cultures. Representative light-microscopy fields of cultures subjected to the treatment are shown
after Wright’s-staining at the times indicated.
Moneriz et al. Malaria Journal 2011, 10:82
http://www.malariajournal.com/content/10/1/82
Page 7 of 10
resistance to chloroquine has been associated to the
acquisition of a mutant transporter PfCRT that is cap-
able of reducing intracellular exposure to the drug [40].
The minor differences observed in the response of Dd2
and 3D7 to MA suggests that PfCRT polymorphisms
yielding resistance to chloroquine do not affect the
activity of maslinic acid.
The incubation of P. falciparum synchronized cultures
with MA at different stages of the intra-erythrocytic
cycle revealed that the presence of 100 μM MA comple-
tely prevents the increase in parasitaemia, leading to
parasite cell death if the compound is present up to
86 hours. Remarkably, even at such high concentration,
the removal of MA after 12 hour incubation led to the
recovery of parasite growth independently of the parasi-
tic stage at treatment, indicating that the effect of this
compound on the cell cycle is reversible, although cul-
tures treated with MA at schizont stage showed the
slowest rate of recovery to normal parasitaemia. This
result is compatible with the possible inhibition of schi-
zont-specific processes. However, the distribution of
parasitic stages observed after the removal of MA at dif-
ferent times suggests a more complex picture. Exposure
to MA at ring-stage generates accumulation of ring
forms and the delay of appearance of trophozoites sug-
gesting that MA inhibition takes place as soon as ring
stage. A comparable accumulation of trophozoite and
schizont forms are observed after treatments at tropho-
zoite and schizont stages, respectively. Two possible
situations may explain this behavior of MA on the infec-
tion: either the putative target for MA is a process
which takes place along the whole erythrocytic cycle or,
alternatively, the compound may display a multiple-tar-
get activity, affecting sequentially processes occurring at
ring-trophozoite and schizont stages. While ring-tropho-
zoite stages are characterized by massive hemoglobin
ingestion, intake of nutrients from the surrounding
medium and formation of organelles, schizonts are char-
acterized by DNA replication and the beginning of
maturation of merozoite cells with the appearance of
merozoite organelles, such as rhoptry and dense gran-
ules. Genes expressed preferentially at ring-trophozoite
or schizont stages have been identified [41] and may
constitute potential targets for the observed activity of
MA. Hence, it can be hypothesized that the observed
hindering of plasmodial infection progress may be
explained as a consequence of proteases and/or phos-
phatases inhibition, in accordance with previous activ-
ities reported for MA and other related triterpenoid
molecules [17,22,24,42]. Other possible targets, such as
plasmodial topoisomerases [43] or the inhibition of iso-
prenoid biosynthesis, reported for various terpenes [44],
can not be discarded as they may be essential in the
processes leading to the development of merozoites.
Maslinic acid displays dose-dependent effect on Plas-
modium. Long incubations (48 h) with MA at IC50
range, or short incubations (12 h) with 3X IC50 concen-
trations lead to the growth arrest of the parasite, while
long incubations, even at 1.7X IC50, yield non-viable
Figure 5 Effect of maslinic acid treatment at different infection
periods in the accumulation of P. falciparum erythrocytic
stages. Bars show the percentage of rings (white), trophozoites
(grey), schizonts (black) and pyknotic (hatched) forms observed after
12 h incubation with 100 μM MA at ring (R+MA), trophozoite (T
+MA) and schizont (S+MA) stages. Data collected by microscopic
inspection of Wright’s-stained blood smears and compared with
controls untreated (top) and cultivated in the presence of 100 μM
MA throughout the whole experiment (bottom). The percent of
each group accounts for the fraction of cells showing every parasite
stage out of a total of 1,000 erythrocytes. Results are representative
of two experiments.
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cells. Unlike antibiotics inhibiting protein synthesis or
DNA gyrase activity, which do not lead to phenotypic
effects at the end of the first cycle but cause a delayed
effect by rendering nonfunctional apicoplasts and schi-
zont arrest in the progeny [45-48], MA appears to exert
a non-delayed inhibition of maturation on first-cycle
parasites, suggesting different MA-targets to those
reported for slow-action antibiotics. The in vitro parasi-
tostatic effect of MA was reproduced in vivo using a
murine malaria model (Moneriz et al, accompanying
paper). The use of parasitostatic drugs have not been
explored sufficiently as a potential anti-malarial treat-
ment. The interruption of the parasite cycle during the
erythrocytic phase should enhance the development of a
protective response in the host by extension of the time
in which the antigens are exposed to the immune sys-
tem. Such enhanced acquisition of immunity in mice
treated with MA is shown in the accompanying report
by Moneriz et al. Thus, anti-malarial drugs which speci-
fically interrupt the parasite development maintaining
the exposure of antigens may, therefore, become a kind
of combined treatment-vaccination approach by using a
single compound.
From the results reported in this work, it can be pro-
posed that maslinic acid may be a valuable lead com-
pound to develop a new class of drugs targeting
unexploited plasmodial pathways. Following a reverse
approach, these molecules would allow to identify and
test novel targets for drug development. By comparison
of the structures and the activities exhibited by masli-
nic acid and related molecules, it would be feasible to
identify the structural characteristics essential for their
anti-parasitic activity and, subsequently, use the natural
products as lead compounds for the synthesis of new
drugs.
Conclusions
Maslinic acid emerges as a novel Plasmodium parasito-
static natural compound, affecting the whole process of
parasite maturation throughout the intraerythrocytic
cycle and inhibiting merozoite egression at the IC50
range. The growth arrest can be released by elimination
of the compound from the culture medium, allowing
the parasite to proceed through the subsequent infective
stages. Taking into account the parasitostatic effect
observed from ring to schizont stages, a multiple-target
action on P. falciparum is proposed for MA, likely
including the inhibition of protease activities essential
for growth. The use of parasitostatic agents alone or in
combination with other anti-malarial compounds may
fuel the development of new therapeutic strategies
encompassing the presentation of parasite antigens to
the host immune system.
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